This study is being conducted in Mali, Africa.
Pneumonia is a respiratory infection of the lungs caused by bacteria or virus. Some children can develop signs of severe pneumonia and as a result, have difficulty breathing and low levels of oxygen in the blood. In some cases this can progress to death. Patients with signs of severe pneumonia require admission to the hospital for treatment and the treatment includes delivery of oxygen. Currently, in the hospital, oxygen is available for delivery by nasal cannula to children. In this case, oxygen is given through a small plastic tube which delivers oxygen through the nose. However, the amount of oxygen that can be given is limited because of the size of the tube and the amount of oxygen that can go through. However, a new device known as the bubble CPAP machine delivers oxygen through the nose in a way that helps the airways to stay open. This is known to provide better support to children less than 1 year of age who have difficulty breathing with signs of severe pneumonia. The purpose of this study is to evaluate the effectiveness of bubble CPAP in Children up to 5 years of age with with signs of severe pneumonia.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pneumonia | Device: Bubble CPAP Other: Standard Therapy | Not Applicable |
This study includes two cohorts. One cohort will participate in an interventional clinical trial and the other cohort will participate in an observational study.
Interventional Cohort:
The first cohort will include 600 children with signs of severe pneumonia, 1 year up to 5 years of age. Signs of severe pneumonia include fast breathing, difficulty breathing and who are very sick (not able to drink, vomiting, having seizures, are very sleepy or with severe malnutrition). Two out of every three children will receive oxygen with the bubble CPAP and one out of every three children will receive treatment with oxygen with regular nasal cannula. The treatment assignment will be determined randomly. We will follow up participants during their entire hospitalization. During this time we will collect information on the child's illness, test results and treatment.
Observational Cohort:
The second cohort will include 450 children with signs of severe pneumonia, under 1 year of age. In Mali, bubble CPAP is currently given as standard of care (when possible) for children with signs of severe pneumonia, under 1 year of age; therefore, children in this cohort will already be receiving bubble CPAP as standard of care prior to enrollment. The only research activities will be to follow the children during their hospitalization and collect information about their clinical condition, test results, treatment and the amount of oxygen required during the hospital admission.
The remainder of the information in this ClinicalTrials.gov registration will refer only to the Intervention Cohort.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This is an unblinded, age-stratified, randomized trial with a 2:1 allocation ratio. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Use of Bubble Continuous Positive Airway Pressure (bCPAP) With High Flow Settings in Treatment of Respiratory Distress Secondary to Signs of Severe Pneumonia in Pediatric Patients in Mali |
Actual Study Start Date : | September 26, 2019 |
Actual Primary Completion Date : | September 30, 2019 |
Actual Study Completion Date : | September 30, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Bubble CPAP |
Device: Bubble CPAP
Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
|
Standard Therapy |
Other: Standard Therapy
For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 < 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
|
We define treatment failure as the occurrence of any two or more of the following clinical criteria 2 hour after initiation of an intervention:
Increased in respiratory rate by any amount or if respiratory rate remains unchanged after initiation of treatment as follow:
Ages Eligible for Study: | 12 Months to 5 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Cases must meet the all following inclusion criteria for eligibility to be placed on bCPAP
Fast breathing defined as: (Using a timing device to count rate for one full minute)
With cough AND/OR any sign of difficult breathing Plus ONE general danger sign as follow:
Patients with the following conditions who meet eligible criteria can benefit from bCPAP:
We will include patients with progression to severe pneumonia during the hospitalization and those ones with chronic diseases too.
Definitions:
Exclusion criteria:
Cases that meet any of the following exclusion criteria will be ineligible to enroll:
Mali | |
Center for Vaccine Development - Mali | |
Bamako, Mali |
Principal Investigator: | Adnan T Bhutta, MBBS | University of Maryland, Baltimore |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | April 22, 2019 | ||||
First Posted Date ICMJE | May 9, 2019 | ||||
Last Update Posted Date | June 9, 2020 | ||||
Actual Study Start Date ICMJE | September 26, 2019 | ||||
Actual Primary Completion Date | September 30, 2019 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Treatment failure rate [ Time Frame: 2 hours ] We define treatment failure as the occurrence of any two or more of the following clinical criteria 2 hour after initiation of an intervention:
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
Mortality rate [ Time Frame: Through hospital discharge, an average of 1 week ] The difference in mortality between the standard therapy group vs bCPAP group at the time of discharge.
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa | ||||
Official Title ICMJE | Use of Bubble Continuous Positive Airway Pressure (bCPAP) With High Flow Settings in Treatment of Respiratory Distress Secondary to Signs of Severe Pneumonia in Pediatric Patients in Mali | ||||
Brief Summary |
This study is being conducted in Mali, Africa. Pneumonia is a respiratory infection of the lungs caused by bacteria or virus. Some children can develop signs of severe pneumonia and as a result, have difficulty breathing and low levels of oxygen in the blood. In some cases this can progress to death. Patients with signs of severe pneumonia require admission to the hospital for treatment and the treatment includes delivery of oxygen. Currently, in the hospital, oxygen is available for delivery by nasal cannula to children. In this case, oxygen is given through a small plastic tube which delivers oxygen through the nose. However, the amount of oxygen that can be given is limited because of the size of the tube and the amount of oxygen that can go through. However, a new device known as the bubble CPAP machine delivers oxygen through the nose in a way that helps the airways to stay open. This is known to provide better support to children less than 1 year of age who have difficulty breathing with signs of severe pneumonia. The purpose of this study is to evaluate the effectiveness of bubble CPAP in Children up to 5 years of age with with signs of severe pneumonia. |
||||
Detailed Description |
This study includes two cohorts. One cohort will participate in an interventional clinical trial and the other cohort will participate in an observational study. Interventional Cohort: The first cohort will include 600 children with signs of severe pneumonia, 1 year up to 5 years of age. Signs of severe pneumonia include fast breathing, difficulty breathing and who are very sick (not able to drink, vomiting, having seizures, are very sleepy or with severe malnutrition). Two out of every three children will receive oxygen with the bubble CPAP and one out of every three children will receive treatment with oxygen with regular nasal cannula. The treatment assignment will be determined randomly. We will follow up participants during their entire hospitalization. During this time we will collect information on the child's illness, test results and treatment. Observational Cohort: The second cohort will include 450 children with signs of severe pneumonia, under 1 year of age. In Mali, bubble CPAP is currently given as standard of care (when possible) for children with signs of severe pneumonia, under 1 year of age; therefore, children in this cohort will already be receiving bubble CPAP as standard of care prior to enrollment. The only research activities will be to follow the children during their hospitalization and collect information about their clinical condition, test results, treatment and the amount of oxygen required during the hospital admission. The remainder of the information in this ClinicalTrials.gov registration will refer only to the Intervention Cohort. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Not Applicable | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: This is an unblinded, age-stratified, randomized trial with a 2:1 allocation ratio. Masking: None (Open Label)Primary Purpose: Treatment |
||||
Condition ICMJE | Pneumonia | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Terminated | ||||
Actual Enrollment ICMJE |
13 | ||||
Original Estimated Enrollment ICMJE |
600 | ||||
Actual Study Completion Date ICMJE | September 30, 2019 | ||||
Actual Primary Completion Date | September 30, 2019 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion criteria: Cases must meet the all following inclusion criteria for eligibility to be placed on bCPAP
Patients with the following conditions who meet eligible criteria can benefit from bCPAP:
We will include patients with progression to severe pneumonia during the hospitalization and those ones with chronic diseases too. Definitions:
Exclusion criteria: Cases that meet any of the following exclusion criteria will be ineligible to enroll:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 12 Months to 5 Years (Child) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Mali | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03944551 | ||||
Other Study ID Numbers ICMJE | HP-82800 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Responsible Party | Adnan Bhutta, University of Maryland, Baltimore | ||||
Study Sponsor ICMJE | University of Maryland, Baltimore | ||||
Collaborators ICMJE | Center for Vaccine Development - Mali | ||||
Investigators ICMJE |
|
||||
PRS Account | University of Maryland, Baltimore | ||||
Verification Date | June 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |